Plectin is a linker protein that interacts with intermediate filaments and 4 integrin in hemidesmosomes of the epidermal basement membrane zone (BMZ). Type XVII collagen (COL17) has been suggested as another candidate plectin binding partner in hemidesmosomes. Here, we demonstrate that plectin-COL17 binding helps to maintain epidermal BMZ organization. We identified an epidermolysis bullosa (EB) simplex patient as having markedly diminished expression of plectin and COL17 in skin. The patient is compound heterozygous for sequence variants in the plectin gene (PLEC); one is a truncation and the other is a small in-frame deletion sequence variant. The in-frame deletion is located in the putative COL17-binding domain of plectin and abolishes the plectin-COL17 interaction in vitro.
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PA) and skin-only EBS (Gostynska, et al., 2015; Natsuga, 2015; Winter and Wiche, 2013) .
Here, we present an EBS patient with a plectin disease-causing sequence variant in the COL17-binding domain and demonstrate that the sequence variant disturbs the interaction between plectin and COL17 in vitro.
The proband was born to non-consanguineous Japanese parents. He had suffered from skin fragility since birth. In the first week of life, erosions and small blisters were seen on his trunk and extremities (Supp. Fig. S1a-b) . His developmental status was otherwise normal, and no muscle weakness or gastrointestinal complications were observed in the first 3 years of life. Electron microscopy of skin specimens from the proband revealed skin detachment within basal keratinocytes accompanied by hypoplastic hemidesmosomes at the bottom of the blisters (Supp. Fig. S1c-e) . Keratin aggregates were not present in the cytoplasm of the keratinocytes. The clinical manifestations and ultrastructural findings led to the diagnosis of EBS, basal subtype (Fine, et al., 2014) .
To identify the targeted protein in this EBS case, we evaluated the expression of various BMZ proteins in the proband's skin (Supp. Fig. S2a-h ) (Natsuga, et al., 2010a) . We found that plectin staining in the epidermal BMZ was 6 diminished compared with that of normal control skin (Supp. Fig. S2a-c) as determined using several antibodies directed to different portions of the plectin molecule. In addition, COL17 labeling in skin samples from the proband was also reduced relative to that of skin samples from the control subject. In contrast, 4 integrin labeling in proband tissue was comparable to control tissue (Supp. 
S2d-h). The expression patterns of other BMZ proteins, including BP230, 6
integrin, type IV collagen, laminin-332 and type VII collagen, were not affected (data not shown). To confirm the results obtained from the skin specimens, we evaluated cultured epidermal keratinocytes collected from the proband and the control patient. Immunoblot analysis revealed that expression of plectin and COL17 was reduced in the proband's keratinocytes compared with the control, whereas expression of 4 integrin was unaffected ( Fig. 1a-d (Winter, et al., 2016) (Fig. 1e) and previously undescribed c.9194dup
(p.Ser3066GlufsTer55) in exon 32 (Fig. 1f) . The proband's mother and father were carriers for a heterozygous allele of c.2264_2266del or c.9194dup, respectively (data not shown). These sequence variants were submitted to the public Leiden Open Variation Database 3.0 (https://databases.lovd.nl/shared/individuals/00119121). Generally, truncation sequence variants that lead to premature termination codons in the last exon of the gene have been regarded as being exempt from nonsense-mediated mRNA decay. However, previous studies suggested that truncation sequence variants in exon 32 might be subject to nonsense-mediated mRNA decay (Natsuga, et al., 2010b) , possibly through microRNA-regulated mRNA qualification (Zhao, et al., 2014) . Therefore, c.9194dup in exon 32 is expected to lead to null expression of the allele (Fig. 1g) . In contrast, c.2264_2266del (p.Phe755del) is an in-frame deletion that is not expected to affect gene expression (Fig. 1g) . p.Phe755del is 8 located in the Y domain of plectin (Arg618 to Val819), which was predicted to be a COL17-binding domain by the yeast two-hybrid assay (Koster, et al., 2003) (Fig.   1g) . Although c.2264_2266del is adjacent to the splice acceptor site, PCR products derived from the cDNA of proband and control keratinocytes spanning the exon18-exon19 junction exhibited a single band (Supp. Fig. S3a ). Direct sequencing of the PCR products revealed a wild type and a c.2264_2266del
allele (Supp. Fig. S3b ), suggesting that PLEC splicing is not altered by c.2264_2266del. Along with the null expression of one allele of PLEC, these findings indicate that an in-frame deletion in the putative COL17-binding domain of plectin is disease-causing for the EBS phenotype.
Quantitative RT-PCR revealed that PLEC gene expression was reduced in keratinocytes cultured from the proband (Supp. Fig. S4a ), which is consistent with the sequence variant data and protein expression studies. Expression of a major transcript variant of PLEC expressed in the hemidesmosome (encoding plectin 1a isoform) was reduced in keratinocytes from the proband (Supp. Fig.   S4b ). Unexpectedly, COL17A1 gene expression was also diminished in the proband's cells compared with control cells (Supp. Fig. S4c ).
In light of the results of genetic analyses, we hypothesized that the in-frame 9 deletion of plectin in the putative COL17-binding domain specifically hinders plectin-COL17 binding. To test this hypothesis, we prepared three V5-tagged vectors with PLEC cDNA fragments: 1) PLEC1-819, 2) PLEC1-617 and 3) PLEC1-819Phe755 (Fig. 2a) (Koster, et al., 2003) (Fig. 2b) . failed to bind to COL17 in the transfected cells (Fig. 2b) . To further investigate the interaction between plectin and COL17, GST-tagged recombinant partial plectin and the full-length COL17 (FLAG-COL17) recombinant proteins were subjected to a protein-protein binding assay (Fig. 2c) . The full-length COL17
(FLAG-COL17, input) was detected at approximately 180 kDa with CBB staining (Fig. 2d) . GST (~25 kDa) and GST-tagged partial plectin proteins (PLEC618-819 and PLEC618-819755Phe, both ~50 kDa) were also detected with CBB.
PLEC618-819 was bound to FLAG-COL17, but the binding of PLEC618-819755Phe to FLAG-COL17 was significantly diminished (Fig. 2d, 2e) . These results indicate that in-frame deletion of Phe755 in the COL17-binding domain greatly reduces plectin-COL17 binding.
In addition to the p.Phe755del detected in the proband and in the recent case series (Winter, et al., 2016) , several other EBS cases with PLEC in-frame deletion/insertion sequence variants have been described: 1) c.954_956dup
c.1530_1531insGTCTGCGTGTACCGTCTGCTCCGACGCCTGGTAGGC
(p.Ala510_Ile511insValCysValTyrArgLeuLeuArgArgLeuValGly) in exon 14 (the detailed information kindly provided by Prof. Jouni Uitto) (Pfendner, et al., 2005) , and 3) c.2677_2685del (p.Gln893_Ala895del) in exon 21 (Pulkkinen, et al., 1996; Yiu, et al., 2011) . p.Leu319dup is near the actin-binding domain (ABD), to which 4 integrin primarily binds (Geerts, et al., 1999; Rezniczek, et al., 1998) ; this sequence variant has been shown to lead to protein self-aggregation and impaired binding between 4 integrin and plectin (Bauer, et al., 2001 ).
(p.Ala510_Ile511insValCysValTyrArgLeuLeuArgArgLeuValGly) (Pfendner, et al., 2005 ) is localized in the plakin domain but outside the putative COL17-binding domain (Arg618 to Val819). p.Gln893_Ala895del was previously described as being located within the Y domain of plectin (Koster, et al., 2003) , but the sequence variant is apparently outside the Arg618 to Val819 region. This is in line with immunofluorescence data showing normal COL17 labeling on the BMZ of an EBS patient with p.Gln893_Ala895del (Pulkkinen, et al., 1996) . Thus, to our knowledge, the p.Phe755del detected in the proband in the current study is the first disease-causing sequence variant to be identified within the putative COL17-binding domain of plectin.
The intracytoplasmic in-frame deletion of COL17 has also been reported to contribute to an EBS phenotype (Fontao, et al., 2004) . This deletion abolishes the association of COL17 with plectin together with 4 integrin and BP230 (Fontao, et al., 2004) . In addition, COL17-null cultured keratinocytes fail to incorporate plectin into hemidesmosome-like structures (Koster, et al., 2003) .
These studies also support the importance of the plectin-COL17 interaction in 12 hemidesmosome formation in vitro. Our study highlighted the significance of the plectin-COL17 interaction in vivo.
As flawed protein-protein interactions affect protein stability, the reduced protein levels of plectin and COL17 together with the maintenance of 4 integrin are consistent with a defective plectin-COL17 interaction due to a PLEC sequence variant in the COL17-binding domain. However, gene expression levels of plectin and COL17 were also diminished in cells cultured from the proband. Given that plectin knockdown in normal human epidermal keratinocytes does not alter COL17 gene expression (data not shown), the reason for the reduction in COL17 gene expression in the proband's cells remains unclear, although it might be associated with other sequence variants in proband cells.
In addition to binding to the ABD (Geerts, et al., 1999; Rezniczek, et al., 1998) , 4 integrin may also bind to other domains of plectin Rezniczek, et al., 1998) . Although the plakin domain of plectin was reported to bind to 4 integrin in a blot overlay assay (Rezniczek, et al., 1998) , the binding was not confirmed in a yeast two-hybrid assay (Takeichi, et al., 2015) .
Therefore, the defective protein-protein binding seen in our study may contribute to the pathology in some undiagnosed EBS cases.
In conclusion, our study is the first to detect a plectin disease-causing sequence variant within the COL17-binding domain in EBS. Abnormalities in the protein-binding domain may disturb the formation of cell structures, leading to devastating diseases such as EB. 
Materials and Methods

Electron microscopy
Ultrastructural observation was performed as described previously (Natsuga, et al., 2011) . Briefly, skin biopsy samples were fixed in 5% glutaraldehyde solution,
followed by post-fixation in 1% OsO4. After dehydration, samples were embedded in Epon 812 (TAAB, UK) and sectioned for electron microscopy.
Ultrathin sections were stained with uranyl acetate and lead citrate and examined via JEM1400 transmission electron microscopy (Tokyo, Japan).
Antibodies
The following antibodies were used: monoclonal antibody (mAb) PN643 against the N-terminus of plectin; mAb HD1-121 against the rod domain of plectin; mAb PC815 against the C-terminus of plectin; mAb 3E1 (Chemicon International, Temecula, CA) and polyclonal antibody (polyAb) H101 (Santa Cruz Biotechnology, Santa Cruz, CA) against 4 integrin; mAb 1A8c against the cytoplasmic portion of COL17; polyAb 11-NC16A-R1 against the NC16A domain of COL17; mAb D20 against the C15 domain of COL17; mAb 233 and polyAb 09040 against the C-terminus of COL17; mAb GoH3 (Chemicon International, CA) against 6 integrin; mAb GB3 (Sera-lab, Cambridge, UK) against laminin 332; mAb LH7.2 (Sigma, St. Louis, MO) against type VII collagen; mAb PHM-12+CIV22 against type IV collagen (NeoMarkers, Fremont, CA); polyAb S1193 against BP230; mAb AC15 against -actin (Sigma, St. Louis, MO); polyAb ab6046 (abcam, Cambridge, UK) against tubulin; anti-V5 antibody (Invitrogen); and mAb M2 against FLAG (Sigma). The details of mAbs PN643, HD1-121, PC815, 1A8c, D20 and 233 were described in previous reports (Gache, et al., 1996; Hirako, et al., 1998; . 11-NC16A-R1
and 09040 were prepared as described previously (Natsuga, et al., 2012; Ujiie, et al., 2014) . S1193 was donated by Prof. J. R. Stanley of the University of Pennsylvania.
Cell culture and immunoblot analysis
Cultured epidermal keratinocytes were obtained from skin biopsy samples and maintained with Cnt-Prime (CELLnTEC, Bern, Switzerland). Cultured keratinocytes were lysed in NP-40-containing buffer (1% NP-40, 25 mM Tris-HCl, 4 mM EDTA, 100 mM NaCl, 1 mM phenylmethylsulfonyl fluoride, and proteinase inhibitor cocktail (Sigma)) on ice for 30 min. Cell debris was removed by centrifugation, and supernatant was collected and mixed with Laemmli's sample buffer. After boiling, samples were separated by gel electrophoresis on a NuPAGE 4-12% Bis-Tris gel (Invitrogen) and transferred to a PVDF membrane.
The membrane was incubated with primary antibodies (HD1-121, 09040, H101
and ab6046) overnight at 4°C followed by incubation with secondary antibodies conjugated with horseradish peroxidase (HRP) for 1 hr at room temperature. The blots were detected using Clarity Western ECL Substrate (Bio-rad). The band intensity was calculated using ImageJ.
Immunofluorescence
For staining of skin samples, skin biopsy specimens were embedded in optimal cutting temperature (OCT) compound and quickly frozen with dry ice.
Five-micron cryostat sections were incubated with primary antibodies (1A8c, 11-NC16AR1, D20, 233, PN643, HD121, PC815 and H101) overnight at 4°C.
After washing in PBS, sections were incubated with secondary antibodies conjugated with fluorescein-isothiocyanate (FITC) or Alexa488 for 1 hr at room temperature. All stained samples were imaged with a confocal laser scanning microscope (Olympus Fluoview FV1000).
Sequence variant analysis
Genomic DNA extracted from peripheral blood was used as a template for polymerase chain reaction (PCR) amplification. All coding exons including exon-intron boundaries of PLEC (Nakamura, et al., 2005) , COL17A1 (Gatalica, et al., 1997) , ITGB4 (Takizawa, et al., 1997) , KRT5/KRT14 (Hut et al., 2000; Stephens et al., 1997) , DST (Groves, et al., 2010) , and EXPH5 (Pigors, et al., 2014) were amplified according to previously described methods. DNA sequencing of the PCR products was performed with an ABI 3100 sequencer (PerkinElmer Life Sciences-ABI, Foster City, CA Val819 was subcloned into pGEX6P-1 (GE Healthcare) (PLEC618-819).
Constructs with PLEC cDNA harboring p.Phe755del (PLEC1-819Phe755 or PLEC618-819Phe755) were generated using the GeneTailor Site-Directed Mutagenesis System (Invitrogen) on PLEC1-819 or PLEC618-819.
Immunoprecipitation-immunoblot assay
HEK293 cells stably expressing COL17-FLAG were prepared as described previously (Li, et al., 2010) . Plasmids were transfected into HEK293 cells using Lipofectamine 2000 (Invitrogen). Cell lysates were obtained using NP-40-containing buffer 48 hours after transfection. For immunoprecipitation, protein-G Sepharose (GE Healthcare) was coupled with anti-V5 antibody, followed by incubation with cell lysates at 4°C overnight. After washing of the beads with PBS containing 0.1% NP-40, bound proteins were eluted by boiling for 5 min with Laemmli's sample buffer. Immunoblotting using anti-V5 antibody or anti-FLAG antibody was performed on the immunoprecipitated samples or the cell lysates mixed with sample buffer as described above. mAb AC15 against -actin was used to confirm equal loading. The band intensity was calculated using ImageJ.
Protein-protein binding assay
The recombinant full-length COL17 with a FLAG-tag on the N-terminus Sepharose was incubated with the recombinant full-length COL17 in the binding buffer at 4°C overnight. After washing, the Sepharose was boiled with Laemmli's sample buffer and centrifuged. The supernatants were separated by gel electrophoresis as described above, and the gels were stained with CBB or used for subsequent immunoblotting using anti-FLAG antibody. The band intensity was calculated using ImageJ (https://imagej.nih.gov/ij/) (Schneider, et al., 2012) .
Statistics
Statistical analysis was performed using GraphPad Prism (GraphPad Software, CA). P values were determined with Student's t-test. P-values are indicated as *0.01<p<0.05, **0.001<p<0.01.
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